Revisiting niacin: reviewing the evidence

Journal of Clinical Lipidology

Volumn 1, Issue 4, 2007, Pages 248-255

  Vaccari, Christopher S ^a   Hammoud, Ramadan A ^a   Nagamia, Sameer H ^a   Ramasamy, Kanni ^a   Dollar, Allen L ^a   Khan, Bobby V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Metabolic syndrome; Niacin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CLOFIBRATE; COLESTIPOL; DEXTROTHYROXINE; DIACYLGLYCEROL ACYLTRANSFERASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN; FIBRIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; FIBRINOLYSIS; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN SENSITIVITY; LIVER TOXICITY; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK REDUCTION; SIDE EFFECT; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 34548427789     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.07.008     Document Type: Review

References (68)

1. Tenenbaum A., Fishman E.Z., Motro M., and Yehuda A. Atherogenic dyslipidemia in the metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 5 (2006) 20
2. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 256 (1986) 2835-2838
3. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
4. Morrow J.D., Parsons III W.G., and Roberts II L.J. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38 (1989) 263-274
5. Meyers C.D., Carr M.C., Park S., and Brunzell J.D. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 139 (2003) 996-1002
6. Coronary Drug Research Project Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
7. Piepho R.W. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 86 suppl (2000) 35L-40L
8. McKenney J.M., Proctor J.D., Harris S., and Chinchili V.M. Comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271 (1994) 672-677
9. Knopp R.H. Evaluating niacin in its various forms. Am J Cardiol 86 suppl (2000) 51L-56L
10. Nofer J.-R., Kehrel B., Fobker M., Levkau B., Assmann G., and Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161 (2002) 1-16
11. Kwiterovich P. The antiatherogenic role of high density lipoprotein cholesterol. Am J Cardiol 82 (1998) 13-21Q
12. Yuhanna I.S., Zhu Y., Cox B.E., et al. High density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat Med 7 (2001) 853-857
13. Li X.P., Zhao S.P., Zhang X.Y., Liu L., Gao M., and Zhou Q.C. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 73 (2000) 231-236
14. Parthasarathy S., Barnett J., and Fong L. High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochem Biophys Acta 1044 (1990) 275-283
15. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Thromb Vasc Biol 15 (1995) 1987-1994
16. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., and Tomvall P. Mild to moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38 (2001) 111-116
17. Gaenzer H., Sturm W., Neumayr G., et al. Pronounced postprandial lipemia impairs endothelium dependent dilation of the brachial artery in men. Cardiovasc Res 52 (2001) 509-516
18. Toikka J.O., Ahotupa M., Viikari J.S.A., et al. Constantly low HDL cholesterol concentrations relate to endothelial dysfunction and increase in vivo LDL-oxidation in healthy young men. Atherosclerosis 147 (1999) 133-138
19. Suwaidi J.A., Hamasaki S., Higano S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
20. Watanabe H., Soderlund S., Soro-Paavonen A., et al. Decreased high-density lipoprotein (HDL) particle size, Pre β-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thomb Vasc Biol 26 (2006) 897-902
21. Birjmohun R.S., Hutten B.A., Kastelein J.J.P., and Stroes E.S.G. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. J Am Coll Cardiol 45 (2005) 185-197
22. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscl Thomb Vasc Biol 17 (1997) 2020-2028
23. Sakai T., Kamanna V.S., and Kashyap M.L. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 21 (2001) 1783-1789
24. Kuvin J.T., Dave D.M., and Sliney K.A. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 98 (2006) 743-745
25. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1) trial. Am J Cardiol 90 (2002) 89-94
26. Yu B.L., and Zhao S.P. Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects. Med Hypotheses 69 (2007) 90-94
27. Ganji S.H., Tavintharan S., Zhu D., Xing Y., Kamanna V.S., and Kashyap M.L. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45 (2004) 1835-1845
28. Rubic T., Trottmann M., and Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67 (2004) 411-419
29. Tunaru S., Schaub A., Wufka C., Blaukat A., Pfeffer K., and Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 (2003) 352-355
30. Tomoda H., and Aoki N. Prognostic value of C-reactive protein levels within six hours after onset of acute myocardial infarction. Am Heart J 140 (2000) 324-328
31. Ridker P.M., Hennekens C.H., and Buring J.E. C-reactive protein and other markers of inflammation in the prediction of cardio-vascular disease in women. N Engl J Med 342 (2001) 836-843
32. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial (ADVENT). Arch Intern Med 162 (2002) 1568-1576
33. Westphal S., Borucki K., Taneva E., Makarova R., and Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 193 (2007) 361-365
34. Salmenniemi U., Ruotsalainen E., Pihlajamaki J., et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110 (2004) 3842-3848
35. Kumada M., Kihara S., Sumitsuji S., et al. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
36. Brown S.L., Sobel B.E., and Fujii S. Attenuation of synthesis of plasminogen activator inhibitor type 1 by niacin: a potential link between lipid lowering and fibrinolysis. Circulation 92 (1995) 767-772
37. Chesney C.M., Elam M.B., Herrd J.A., et al. Effect of niacin, warfarin and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am J Cardiol 140 (2000) 631-636
38. Quyyumi A., Dakak N., Andrews N.P., Gilligan D.M., Panza J.A., and Cannon III R.O. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 92 (1995) 320-326
39. Westphal S., Borucki K., Luley C., Martens-Lobenhoffer J., and Bode-Boger S.M. Treatment with niacin lowers ADMA. Atherosclerosis 184 (2006) 448-450
40. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelium-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
41. Kuvin J.T., Ramet M.E., Patel R.A., Pandian N.G., Mendelsohn M.E., and Karas R.H. A novel mechanism for beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144 (2002) 165-172
42. Benjo A.M., Maranh R.C., Coimbra R.S., et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis 187 (2006) 116-122
43. Miettinen T.A., Taskinen M.-R., Pelkonen R., and Nikkila E.A. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 186 (1969) 247-253
44. Kelly J.J., Lawson G.A., Campbell L.V., et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 14 (2000) 567-572
45. Poynten A.M., Gan S.K., Kriketos A.D., et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52 (2003) 699-704
46. Garg A., and Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. JAMA 264 (1990) 723-726
47. Vega G.L., Cater N.B., Meguro S., and Grundy S.M. Influence of extended release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95 (2005) 1309-1313
48. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284 (2000) 1263-1270
49. Canner P.L., Furberg C.D., Terrin M.L., and McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction. (from the Coronary Drug Project). Am J Cardiol 95 (2005) 254-257
50. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
51. Al Shaer M.H., and Jerome W.P. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study. Am J Cardiol 98 (2006) 275-276
52. Bantle J.P., Wylie-Rosett J., Albright A.L., et al. Nutrition recommendations and interventions for diabetes-2006: a position statement of the American Diabetes Association. Diabetes Care 29 (2006) 2140-2157
53. Altschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 54 (1955) 558-559
54. Genest Jr. J., McNamara J.R., Ordovas M.J.M., et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 19 (1992) 792-802
55. The Coronary Drug Project Research Group. The Coronary Drug Project: design, methods, and baseline results. Circulation 47 (1973) 1-50
56. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
57. Carlson L.A., and Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988) 405-418
58. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., and Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987) 3233-3240
59. Cashin-Hamphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., and Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264 (1990) 3013-3017
60. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., and Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264 (1990) 3007-3012
61. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
62. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
63. Whitney E.J., Krasuski R.A., Personius B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
64. Anne Goldberg A., Alagona P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85 (2000) 1100-1105
65. Bots M.L., and Grobbee D.E. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther 16 (2002) 341-351
66. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
67. Brown B.G. Niaspan® in the management of dyslipidemia: the evidence. Eur Heart J Suppl 8 suppl F (2006) F60-F67
68. Clinical Trials.gov. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available at: www.clinicaltrials.gov/ct/show/NCT00461630?order=1. Accessed June 1, 2007.